PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1252691
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1252691
Gene Expression Market size was valued at USD 8,807.2 Million in 2022, expanding at a CAGR of 10.2% from 2023 to 2030.
Gene expression is a process that allows DNA instructions to be used to create gene products. Reaching the molecular level of each gene is now possible for researchers and scientists due to this method. Gene expression is primarily responsible for the synthesis of proteins, which in turn causes components like proteins, enzymes, and receptors to operate.
The mechanisms of toxicity of the drug and therapeutic candidate toxicity have been extensively investigated using gene expression research and assays. The ability of therapeutic candidates to produce the desired phenotype in leukemia cells can be determined based on post-treatment gene expression, which also aids in identifying the desired drug effect in cancer cells. As a gene expression tool to comprehend the genomics of human cancer, the effects of drug therapy, and the root of treatment failure, spectrometry-based gene expression methods have been created. Gene expression also aids in the molecular redefinition of some diseases, which has helped conventional drug discovery techniques surmount a number of their shortcomings. The discovery of new drug targets, the ability to predict the function of novel genes, and a better understanding of individual variability in drug response have all been sped up by the development of different gene expression profiles. Over the forecast period, these crucial factors are anticipated to considerably boost market revenue.
In addition, a similar strategy for treating rheumatoid arthritis makes sense given that gene expression has been at the forefront of developments in personalized medicine, especially in the areas of cancer and transplantation. One of the key factors propelling the growth of the Gene Expression Market is the use of genomic expression approaches for precise disease management, such as the detection of DNA sequence variations, transcriptomics, and metabolomics, which also connects epigenetics and personalized medicine.
Based on the process, the cDNA synthesis & conversion process segment is expected to dominate the market during the forecast period. Because there are many different cDNA synthesis kits available to meet the research requirements for the ideal reaction temperature, the number of reactions, and the sample size. Additionally, a rise in the number of cDNA synthesis and library preparation kit product launches is expected to fuel the segment's expansion. For instance, SeqWell introduced the plexWell Single Cell Rapid Kit in February 2021 to facilitate the creation of libraries for single-cell RNA sequencing. The product has significantly improved the Smart-seq2 technique, which uses cDNA synthesis and amplification. Additionally, it contributes to a 75% decrease in the burden of normalization and quality control.
Based on the product, the kits & reagents segment is expected to hold a significant market share over the forecast period. The existence of a large number of businesses providing various kits and reagents for gene exploration is responsible for the segment's significant market share. Agilent Technologies, Inc., for example, provides a wide selection of gene expression microarray sets and reagents. The development of cutting-edge products created for particular uses is another factor in the segment's expansion.
North America is expected to dominate the market during the forecast period owing to the presence of major players such as Thermofisher, Qiagen and others. Key participants are constantly engaged in intensive R&D to create new technology and procedures that use gene expression analysis. For instance, the pharmaceutical company Decibel Therapeutics, Inc. from the United States worked with Regeneron Pharmaceuticals to create DB-OTO. Using an exclusive, cell-selective promoter to control gene expression in cochlear hair cells, the preclinical gene therapy candidate DB-OTO is being created. By 2022, the device is anticipated to start the clinical phase.
In January 2023, the bioinformatics division of QIAGEN, QIAGEN Digital Insights (QDI), recently introduced its QIAGEN CLC Genomics Workbench Premium, which eliminates the data-analysis barrier of next-generation sequencing. By incorporating high analysis speed into the analysis and interpretation of the whole exome sequencing (WES), whole genome sequencing (WGS), and big panel sequencing data, the bottleneck of the NGS data analysis is provided.
This proposed research study on the Gene Expression market provides market size (US$ Million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
The research report elucidates potential growth opportunities across different segments/countries and explains an attractive investment proposition matrix for the Gene Expression market
The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain the Gene Expression market
The impact of COVID-19 on the Gene Expression market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight into the Gene Expression market post-COVID will also be covered.
To give the users of this report a comprehensive view of the Gene Expression market, we have also included a competitive landscape and key innovator analysis for the Gene Expression market.
The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
The report offers detailed company profiling featuring major market participants which will help users to understand the financial information and strategic initiatives of players operating in the Gene Expression market.
In addition, the report also unveils the important acquisitions & mergers, collaborations & joint ventures, new launches, research & development, and regional expansion of major participants involved in the market on global as well as regional levels.
The global Gene Expression market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
The scope of this report covers the market by its major segments, which include as follows:
PerkinElmer, Inc.
Bio-Rad Laboratories
F. Hoffmann-La Roche Ltd.
Illumina, Inc.
QIAGEN
Quest Diagnostics, Inc.
Thermo Fisher Scientific, Inc.
Agilent Technologies
Promega Corp.
GE Healthcare
Luminex Corp.
Takara Bio, Inc.
Danaher Corp.
ELITechGroup
AutoGenomics
GLOBAL GENE EXPRESSION MARKET, BY PROCESS
Sample Collection
Purification
cDNA Synthesis & Conversion
PCR Analysis
Data Analysis & Interpretation
Kits & Reagents
DNA Chip/Microarray
Others
GLOBAL GENE EXPRESSION MARKET, BY CAPACITY
Low- to Mid-Plex
High-Plex
GLOBAL GENE EXPRESSION MARKET, BY TECHNIQUE
RNA Exp.
Promoter Analysis
Protein Exp. & Posttranslational Modification Analysis
Drug Discovery & Development
Clinical Diagnostics
Biotechnology & Microbiology
Others
North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA